The Stanford Clinical Center for the Study of Chronic Pancreatitis, Diabetes, and Pancreatic Cancer

项目摘要/摘要 此申请书旨在续签我们对慢性胰腺炎研究联盟的参与， 糖尿病和胰腺癌(CPDPC)，将使斯坦福临床中心继续其 有成效地招募患者参加该联盟的四项关键临床研究-1)前瞻性 慢性胰腺炎的流行病学和转化学研究评价(续)，2) 慢性胰腺炎的儿童纵向队列研究 儿童胰腺炎：寻找治疗方法(INSPPIRE2)，3)建立新的前瞻性研究 起病糖尿病队列(NOD)，以及4)混合餐试验的诊断和评价 继发于胰腺癌和慢性胰腺炎的胰源性糖尿病的特征 胰腺炎(检测)。预期从这些研究中收集的样本将用于进一步 探讨免疫系统在慢性胰腺炎中的作用及其与发病的关系 糖尿病和胰腺癌。 为响应本RFA中所概述的CPDPC联盟的研究目标，我们已经 组建了一支强大的科学团队，在临床、成人和儿科领域具有广泛的互补专业知识 胰腺炎、内分泌学、放射学、初级保健和免疫学。我们的建议是高度 以几种具体方式对RFA作出回应。作为最初联盟的一部分，我们的临床中心， 已经证明有能力有效地将患者招募到CPDPC的4项主要研究中。我们 已经成功地使用存档的样本来展示潜在的免疫信号来诊断 慢性胰腺炎和胰腺癌。在这项新的提案中，我们打算继续验证 这些研究使用了前瞻性收集的样本，这些样本来自于 财团。我们希望最终开发和验证可能有助于诊断的细胞因子图谱 慢性胰腺炎，预测相关并发症的可能性，并导致支持的目标 阻止纤维化的临床试验。对于胰腺癌，这些研究可能导致新的诊断测试 在早期阶段发现胰腺癌。有机会进一步调查和验证这些 与其他中心合作的新观察仍然是一个令人兴奋的改变机会 慢性胰腺炎及其相关并发症的诊断和治疗 胰源性糖尿病和胰腺癌的发展。

Project Summary/Abstract This application to renew our participation in the Consortium for the Study of Chronic Pancreatitis, Diabetes and Pancreas Cancer (CPDPC), will enable the Stanford Clinical Center to continue its productive recruitment of patients into four key clinical studies of the consortium – 1) Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies (PROCEED), 2) Pediatric Longitudinal Cohort Study of Chronic Pancreatitis [The International Study Group of Pediatric Pancreatitis: In Search for a Cure (INSPPIRE2), 3) Prospective Study to Establish a New Onset Diabetes Cohort (NOD), and 4) Evaluation of a mixed meal test for Diagnosis and characterization of Pancreaticogenic Diabetes secondary to pancreatic cancer and chronic pancreatitis (DETECT). Prospectively collected specimens from these studies will be used to further examine the role of the immune system in chronic pancreatitis and its relationship to the development of diabetes and pancreas cancer. In response to the research objectives of the CPDPC Consortium as outlined in this RFA, we have formed a strong scientific team with broad complementary expertise in clinical adult and pediatric pancreatitis, endocrinology, radiology, primary care, and immunology. Our proposal is highly responsive to the RFA in several specific ways. As part of the original Consortium, our Clinical Center, has demonstrated capacity to effectively recruit patients into 4 primary studies of the CPDPC. We have successfully used archived specimens to demonstrate potential immune signals to diagnose chronic pancreatitis and pancreatic cancer. In this renewed proposal, we intend to continue to validate these studies using prospectively collected samples from the prospective longitudinal cohorts of this consortium. We hope to ultimately develop and validate cytokine profiles that may facilitate diagnosis of chronic pancreatitis, predict likelihood of associated complications, and lead to targets to support clinical trials to halt fibrosis. For pancreas cancer, these studies may lead to novel diagnostic tests to detect pancreatic cancer at earlier stages. The opportunity to further investigate and validate these novel observations in collaboration with other centers remains an exciting opportunity to change diagnosis and patient management for chronic pancreatitis and its associated complications of pancreatogenic diabetes and pancreas cancer development.